Physician profile
Reena S John
NPI 1588019962
$13,884.93
in general payments reported to CMS, 2019-2025
30 companies · $581 in 2025
The $581 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $677 · 2021: $5,306 · 2022: $5,528 · 2023: $1,320 · 2024: $473 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,255.45 | 2020-2023 | |
| Abbott Laboratories | $3,132.04 | 2021-2025 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $1,850.60 | 2021-2022 | |
| Spinal Simplicity, LLC | $1,667.79 | 2021-2022 | |
| Painteq LLC | $1,090.03 | 2022-2023 | Painteq |
| Revance Therapeutics, INC. | $394.44 | 2024-2025 | Daxxify |
| Nalu Medical, INC. | $310.99 | 2021 | |
| Merz North America, INC. | $263.29 | 2023 | Xeomin |
| Merck Sharp & Dohme LLC | $244.22 | 2020 | |
| Abbvie INC. | $196.26 | 2022-2024 | |
| Medtronic, INC. | $190.17 | 2021 | |
| Forte Bio-Pharma LLC | $170.65 | 2023-2024 | Prolate, Nalocet |
| Interventional Pain Technologies INC. | $134.45 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $112.15 | 2025 | |
| Medtronic USA, INC. | $110.67 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theragen, INC. | $100.00 | 2023 | Actastim-S |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.07 | 2023-2025 | Relistor |
| Biohaven Pharmaceuticals, INC. | $86.35 | 2021 | |
| Stryker Corporation | $73.48 | 2022 | |
| Virtus Pharmaceuticals LLC | $69.23 | 2024 | Levorphanol Tartrate |
| Collegium Pharmaceutical, INC. | $62.09 | 2021-2023 | Belbuca |
| Nevro Corp. | $52.65 | 2021 | |
| Galderma Laboratories, L.P. | $52.25 | 2023-2024 | Dysport |
| Redhill Biopharma INC. | $33.60 | 2021 | |
| Valinor Pharma, LLC | $31.41 | 2024 | Movantik |
| Almatica Pharma LLC | $30.54 | 2021 | |
| Saluda Medical Americas, INC. | $24.97 | 2024 | Evoke |
| Foundation Fusion Solutions, LLC | $21.03 | 2023 | |
| Horizon Therapeutics Plc | $13.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.